1.46
+0.05(+3.55%)
Currency In USD
| Previous Close | 1.41 |
| Open | 1.44 |
| Day High | 1.48 |
| Day Low | 1.42 |
| 52-Week High | 3.75 |
| 52-Week Low | 1 |
| Volume | 125,683 |
| Average Volume | 117,589 |
| Market Cap | 32.68M |
| PE | -0.59 |
| EPS | -2.48 |
| Moving Average 50 Days | 1.21 |
| Moving Average 200 Days | 1.47 |
| Change | 0.05 |
If you invested $1000 in Boundless Bio, Inc. Common Stock (BOLD) since IPO date, it would be worth $96.5 as of October 25, 2025 at a share price of $1.46. Whereas If you bought $1000 worth of Boundless Bio, Inc. Common Stock (BOLD) shares 1 year ago, it would be worth $146M as of October 25, 2025 at a share price of $1.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Boundless Bio, (Nasdaq: BOLD) a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amp
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 05, 2025 8:58 PM GMT
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amp
Boundless Bio Announces Portfolio Prioritization and Runway Extension
GlobeNewswire Inc.
May 23, 2025 8:01 PM GMT
Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clin